Showing 26–50 of 278
FY2025 revenue $11.24bn (+5.7%); operating margin -2.7%; net loss $957.0m.
Continuing operations; operating loss after impairment and restructuring charges.
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Listed (300676.SZ).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue €4.07bn (+2.3%); contributive operating margin (CEBIT) 17.9%; net income €398.0m.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $20.07bn (+19.9%); operating margin 18.0%; net income $2.90bn.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Canon (7751.T) group FY2025 revenue ¥4.62tn (+2.5%); operating margin 9.8%; net income ¥332.1bn.
Medical unit: sales ¥580.6bn (+2.1%), operating profit ¥32.8bn (prior-year loss).
FY2025 revenue €22.46bn (+1.7%); operating margin 9.8%; net income €1.60bn.
Net debt rose to €5.31bn after acquisitions.
FY2026 revenue $254.25bn (+14.0%); operating margin 1.0%; net income $1.71bn.
Cash $4.86bn; debt $8.89bn.
Listed (CCLD).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue C$15.91bn (+8.4%); pre-tax margin 14.1%; net income C$1.66bn.
Net debt C$3.45bn; long-term debt and leases C$4.33bn.